Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.

[1]  L. Collette,et al.  Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. , 2018, The Lancet. Oncology.

[2]  E. Van Cutsem,et al.  Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Ando,et al.  Quality of Life Analysis in Patients With RAS Wild‐Type Metastatic Colorectal Cancer Treated With First‐Line Cetuximab Plus Chemotherapy , 2017, Clinical colorectal cancer.

[4]  A. Hinke,et al.  Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  B. Arnould,et al.  Methods For Analyzing Patient-Reported Outcomes In Oncology Trials , 2016 .

[6]  L. Collette,et al.  Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. , 2016, The Lancet. Oncology.

[7]  F. di Costanzo,et al.  Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study , 2016, Cancer medicine.

[8]  F. Fiteni,et al.  Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Hebbar,et al.  Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial , 2016, PloS one.

[10]  Yunzhi Lin,et al.  Robust inference for responder analysis: Innovative clinical trial design using a minimum p-value approach , 2016, Contemporary clinical trials communications.

[11]  P. Fayers,et al.  Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. , 2016, Journal of clinical epidemiology.

[12]  A. Carrato,et al.  A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Tae Won Kim,et al.  Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. , 2015 .

[14]  E. Van Cutsem,et al.  Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations , 2014, Investigational New Drugs.

[15]  R. Kaiser,et al.  Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis , 2014, BMC Cancer.

[16]  P. Auquier,et al.  Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? , 2013, Quality of Life Research.

[17]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[18]  M. Kenward,et al.  Differential dropout and bias in randomised controlled trials: when it matters and when it may not , 2013, BMJ.

[19]  E. Van Cutsem,et al.  Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. , 2013, European journal of cancer.

[20]  R. Greil,et al.  Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study , 2012, BMC Cancer.

[21]  H. Raspe,et al.  Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA) , 2011, GMS health technology assessment.

[22]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[23]  N. Pavlakis,et al.  Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Sommergruber,et al.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.

[25]  W. Scheithauer,et al.  EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Osoba,et al.  Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  Qi Jiang,et al.  Responder analyses and the assessment of a clinically relevant treatment effect , 2007, Trials.

[28]  Giorgio Reggiardo,et al.  Phase II Trial of Oxaliplatin and Tegafur/Uracil and Oral Folinic Acid for Advanced or Metastatic Colorectal Cancer in Elderly Patients , 2005, Oncology.

[29]  上谷 さゆり.  QOL (Quality of Life) , 2000, International Archives of Allergy and Immunology.

[30]  Andrew Bottomley,et al.  EORTC QLQ-C30 Scoring Manual , 1995 .